Diabetic Foot Ulcer Treatment Market By Product (Wound care dressings, Wound care devices, Biologics, Others), By Type (Neuropathic ulcers, Ischemic ulcers, Neuroischemic ulcers), By End user (Hospitals, Homecare settings, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032
Diabetic foot ulcers are usual and severe complication of diabetes mellitus, affecting tens of millions of human beings globally. They are persistent wounds that increase at the feet of people with diabetes, mainly the ones who've suffer from high blood sugar or underlying diabetic neuropathy (nerve damage) and peripheral arterial sickness. Moreover, the development of a diabetic foot ulcer is frequently multifactorial, related to a combination of factors together with peripheral neuropathy, trauma, pressure and poor wound healing competencies. In addition, high blood sugar levels in diabetes can lead to nerve damage, reducing sensation in the feet, making it difficult for individuals to detect injuries or wounds. Further, poor circulation compromises the delivery of oxygen and nutrients to the feet, impairing wound healing. Furthermore, if left untreated or poorly managed, diabetic foot ulcers can lead to severe complications, including infection, tissue necrosis (death) and in some cases, amputation. The management of diabetic foot ulcers requires a comprehensive approach that includes wound care dressings & devices, off-loading techniques, infection control and addressing underlying factors contributing to the ulcer's development.
The major factors driving the development of the diabetic foot ulcer treatments are increasing number of individuals suffering from diabetic foot ulcers, rise in R & D exercises, and surge in awareness about proper diabetic foot care. The predominance of diabetes is on the rise across the globe, fueled through factors which include sedentary life, unhealthy diets, and growing obesity. Further, delayed periods of high blood sugar level can result in peripheral neuropathy, a condition that harms the nerves in the toes and diminishes sensation. In addition, poor blood circulation, known as peripheral arterial disease, advance impairs wound healing within the feet. These components, combined with the developing diabetic populace, contribute to an expanded frequency of diabetic foot ulcers. For instance, as per, Centers for Disease Control and Prevention (CDC), 2022, almost 12% individuals with diabetes develop diabetic foot ulcers in U.S. Thus, increasing number of individuals suffering from diabetic foot ulcer has driven the request for compelling treatment options and thereby, propelling the development of the diabetic foot ulcer treatment market.
In addition, researchers and medical experts are actively involved in studying the pathophysiology of diabetic foot ulcers, exploring new treatment modalities and improving existing healing procedures. The use of advanced technology has caused the improvement of modern wound care products, bioengineered pores and skin substitutes and off-loading devices. These improvements aim to enhance wound healing, protect infections, and offer better management options for diabetic foot ulcers. Further, there are ongoing studies in field of regenerative medicine, exploring the potential of stem cells, growth factors, and tissue engineering to promote wound healing. The growing funding in research and development activities by pharmaceutical organizations, instructional institutions and healthcare companies has expanded the invention of novel therapeutic strategies, fueling the growth of the market.
Furthermore, surge in awareness about proper diabetic foot care has contributed to the growth of the diabetic foot ulcer treatment market. Healthcare organizations, diabetes associations, and healthcare professionals had been actively raising focus about the importance of foot care in individuals with diabetes. Diabetic foot ulcers can be averted or minimized through regular foot examinations, right shoes, foot hygiene, and early detection of foot ulcers. Furthermore, education campaigns and initiatives aimed at improving foot care practices have led to increased patient awareness and engagement. As individuals become more aware about the risks and consequences of diabetic foot ulcers, they are more anticipated to seek timely medical attention and adhere to preventive measures. This heightened awareness has not only improved patient outcomes but has also driven the demand for diabetic foot ulcer treatment options.
The global diabetic foot ulcer treatment market is segmented into product, type, end user, and region. On the basis of product, the market is categorized into wound care dressings, wound care devices, biologics and others. The wound care devices segment is further categorized into negative pressure wound therapy and others. Based on type, it is categorized into neuropathic ulcers, ischemic ulcers and neuroischemic ulcers. As per end user, it is segregated into hospitals, homecare settings, and others. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
Major key players that operate in the global diabetic foot ulcer treatment market are ConvaTec Group plc, 3M Company, Cardinal Health Inc., Organogenesis Holdings Inc., Smith and Nephew plc., B. Braun SE, Coloplast, Integra LifeSciences Holdings Corporation, Molnlycke Health Care AB, and Essity Aktiebolag AB. The key players have adopted strategies such as acquisition, contract, product launch, and product approval to expand their product portfolio.
Key Benefits for Stakeholders
This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the diabetic foot ulcer treatment market analysis from 2022 to 2032 to identify the prevailing diabetic foot ulcer treatment market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the diabetic foot ulcer treatment market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global diabetic foot ulcer treatment market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Product
Wound care dressings
Wound care devices
Type
Negative pressure wound therapy
Others
Biologics
Others
By Type
Neuropathic ulcers
Ischemic ulcers
Neuroischemic ulcers
By End user
Hospitals
Homecare settings
Others
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
India
Australia
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
Key Market Players
3M Company
B. Braun SE
Cardinal Health Inc.
Coloplast
ConvaTec Group plc
Essity Aktiebolag AB
Integra LifeSciences Holdings Corporation
Molnlycke Health Care AB
ORGANOGENESIS HOLDINGS INC.
Smith and Nephew plc.
Please Note: It will take 7-10 business days to complete the report upon order confirmation.
- CHAPTER 1: INTRODUCTION
- 1.1. Report description
- 1.2. Key market segments
- 1.3. Key benefits to the stakeholders
- 1.4. Research Methodology
- 1.4.1. Primary research
- 1.4.2. Secondary research
- 1.4.3. Analyst tools and models
- CHAPTER 2: EXECUTIVE SUMMARY
- 2.1. CXO Perspective
- CHAPTER 3: MARKET OVERVIEW
- 3.1. Market definition and scope
- 3.2. Key findings
- 3.2.1. Top impacting factors
- 3.2.2. Top investment pockets
- 3.3. Porter’s five forces analysis
- 3.3.1. High bargaining power of suppliers
- 3.3.2. Moderate threat of new entrants
- 3.3.3. Moderate threat of substitutes
- 3.3.4. Low intensity of rivalry
- 3.3.5. High bargaining power of buyers
- 3.4. Market dynamics
- 3.4.1. Drivers
- 3.4.1.1. Increase in prevalence of diabetic foot ulcer
- 3.4.1.2. Technological advancements in wound care management
- 3.4.1.3. Rise in new product launches for diabetic foot ulcer treatment
- 3.4.2. Restraints
- 3.4.2.1. Stringent regulations for manufacturing of wound care products
- 3.4.3. Opportunities
- 3.4.3.1. Growing opportunity in emerging markets
- 3.5. COVID-19 Impact Analysis on the market
- CHAPTER 4: DIABETIC FOOT ULCER TREATMENT MARKET, BY PRODUCT
- 4.1. Overview
- 4.1.1. Market size and forecast
- 4.2. Wound care dressings
- 4.2.1. Key market trends, growth factors and opportunities
- 4.2.2. Market size and forecast, by region
- 4.2.3. Market share analysis by country
- 4.3. Wound care devices
- 4.3.1. Key market trends, growth factors and opportunities
- 4.3.2. Market size and forecast, by region
- 4.3.3. Market share analysis by country
- 4.3.4. Wound care devices Diabetic Foot Ulcer Treatment Market by Type
- 4.4. Biologics
- 4.4.1. Key market trends, growth factors and opportunities
- 4.4.2. Market size and forecast, by region
- 4.4.3. Market share analysis by country
- 4.5. Others
- 4.5.1. Key market trends, growth factors and opportunities
- 4.5.2. Market size and forecast, by region
- 4.5.3. Market share analysis by country
- CHAPTER 5: DIABETIC FOOT ULCER TREATMENT MARKET, BY TYPE
- 5.1. Overview
- 5.1.1. Market size and forecast
- 5.2. Neuropathic ulcers
- 5.2.1. Key market trends, growth factors and opportunities
- 5.2.2. Market size and forecast, by region
- 5.2.3. Market share analysis by country
- 5.3. Ischemic ulcers
- 5.3.1. Key market trends, growth factors and opportunities
- 5.3.2. Market size and forecast, by region
- 5.3.3. Market share analysis by country
- 5.4. Neuroischemic ulcers
- 5.4.1. Key market trends, growth factors and opportunities
- 5.4.2. Market size and forecast, by region
- 5.4.3. Market share analysis by country
- CHAPTER 6: DIABETIC FOOT ULCER TREATMENT MARKET, BY END USER
- 6.1. Overview
- 6.1.1. Market size and forecast
- 6.2. Hospitals
- 6.2.1. Key market trends, growth factors and opportunities
- 6.2.2. Market size and forecast, by region
- 6.2.3. Market share analysis by country
- 6.3. Homecare settings
- 6.3.1. Key market trends, growth factors and opportunities
- 6.3.2. Market size and forecast, by region
- 6.3.3. Market share analysis by country
- 6.4. Others
- 6.4.1. Key market trends, growth factors and opportunities
- 6.4.2. Market size and forecast, by region
- 6.4.3. Market share analysis by country
- CHAPTER 7: DIABETIC FOOT ULCER TREATMENT MARKET, BY REGION
- 7.1. Overview
- 7.1.1. Market size and forecast By Region
- 7.2. North America
- 7.2.1. Key trends and opportunities
- 7.2.2. Market size and forecast, by Product
- 7.2.3. Market size and forecast, by Type
- 7.2.4. Market size and forecast, by End user
- 7.2.5. Market size and forecast, by country
- 7.2.5.1. U.S.
- 7.2.5.1.1. Key market trends, growth factors and opportunities
- 7.2.5.1.2. Market size and forecast, by Product
- 7.2.5.1.3. Market size and forecast, by Type
- 7.2.5.1.4. Market size and forecast, by End user
- 7.2.5.2. Canada
- 7.2.5.2.1. Key market trends, growth factors and opportunities
- 7.2.5.2.2. Market size and forecast, by Product
- 7.2.5.2.3. Market size and forecast, by Type
- 7.2.5.2.4. Market size and forecast, by End user
- 7.2.5.3. Mexico
- 7.2.5.3.1. Key market trends, growth factors and opportunities
- 7.2.5.3.2. Market size and forecast, by Product
- 7.2.5.3.3. Market size and forecast, by Type
- 7.2.5.3.4. Market size and forecast, by End user
- 7.3. Europe
- 7.3.1. Key trends and opportunities
- 7.3.2. Market size and forecast, by Product
- 7.3.3. Market size and forecast, by Type
- 7.3.4. Market size and forecast, by End user
- 7.3.5. Market size and forecast, by country
- 7.3.5.1. Germany
- 7.3.5.1.1. Key market trends, growth factors and opportunities
- 7.3.5.1.2. Market size and forecast, by Product
- 7.3.5.1.3. Market size and forecast, by Type
- 7.3.5.1.4. Market size and forecast, by End user
- 7.3.5.2. France
- 7.3.5.2.1. Key market trends, growth factors and opportunities
- 7.3.5.2.2. Market size and forecast, by Product
- 7.3.5.2.3. Market size and forecast, by Type
- 7.3.5.2.4. Market size and forecast, by End user
- 7.3.5.3. UK
- 7.3.5.3.1. Key market trends, growth factors and opportunities
- 7.3.5.3.2. Market size and forecast, by Product
- 7.3.5.3.3. Market size and forecast, by Type
- 7.3.5.3.4. Market size and forecast, by End user
- 7.3.5.4. Italy
- 7.3.5.4.1. Key market trends, growth factors and opportunities
- 7.3.5.4.2. Market size and forecast, by Product
- 7.3.5.4.3. Market size and forecast, by Type
- 7.3.5.4.4. Market size and forecast, by End user
- 7.3.5.5. Spain
- 7.3.5.5.1. Key market trends, growth factors and opportunities
- 7.3.5.5.2. Market size and forecast, by Product
- 7.3.5.5.3. Market size and forecast, by Type
- 7.3.5.5.4. Market size and forecast, by End user
- 7.3.5.6. Rest of Europe
- 7.3.5.6.1. Key market trends, growth factors and opportunities
- 7.3.5.6.2. Market size and forecast, by Product
- 7.3.5.6.3. Market size and forecast, by Type
- 7.3.5.6.4. Market size and forecast, by End user
- 7.4. Asia-Pacific
- 7.4.1. Key trends and opportunities
- 7.4.2. Market size and forecast, by Product
- 7.4.3. Market size and forecast, by Type
- 7.4.4. Market size and forecast, by End user
- 7.4.5. Market size and forecast, by country
- 7.4.5.1. Japan
- 7.4.5.1.1. Key market trends, growth factors and opportunities
- 7.4.5.1.2. Market size and forecast, by Product
- 7.4.5.1.3. Market size and forecast, by Type
- 7.4.5.1.4. Market size and forecast, by End user
- 7.4.5.2. China
- 7.4.5.2.1. Key market trends, growth factors and opportunities
- 7.4.5.2.2. Market size and forecast, by Product
- 7.4.5.2.3. Market size and forecast, by Type
- 7.4.5.2.4. Market size and forecast, by End user
- 7.4.5.3. India
- 7.4.5.3.1. Key market trends, growth factors and opportunities
- 7.4.5.3.2. Market size and forecast, by Product
- 7.4.5.3.3. Market size and forecast, by Type
- 7.4.5.3.4. Market size and forecast, by End user
- 7.4.5.4. Australia
- 7.4.5.4.1. Key market trends, growth factors and opportunities
- 7.4.5.4.2. Market size and forecast, by Product
- 7.4.5.4.3. Market size and forecast, by Type
- 7.4.5.4.4. Market size and forecast, by End user
- 7.4.5.5. South Korea
- 7.4.5.5.1. Key market trends, growth factors and opportunities
- 7.4.5.5.2. Market size and forecast, by Product
- 7.4.5.5.3. Market size and forecast, by Type
- 7.4.5.5.4. Market size and forecast, by End user
- 7.4.5.6. Rest of Asia-Pacific
- 7.4.5.6.1. Key market trends, growth factors and opportunities
- 7.4.5.6.2. Market size and forecast, by Product
- 7.4.5.6.3. Market size and forecast, by Type
- 7.4.5.6.4. Market size and forecast, by End user
- 7.5. LAMEA
- 7.5.1. Key trends and opportunities
- 7.5.2. Market size and forecast, by Product
- 7.5.3. Market size and forecast, by Type
- 7.5.4. Market size and forecast, by End user
- 7.5.5. Market size and forecast, by country
- 7.5.5.1. Brazil
- 7.5.5.1.1. Key market trends, growth factors and opportunities
- 7.5.5.1.2. Market size and forecast, by Product
- 7.5.5.1.3. Market size and forecast, by Type
- 7.5.5.1.4. Market size and forecast, by End user
- 7.5.5.2. Saudi Arabia
- 7.5.5.2.1. Key market trends, growth factors and opportunities
- 7.5.5.2.2. Market size and forecast, by Product
- 7.5.5.2.3. Market size and forecast, by Type
- 7.5.5.2.4. Market size and forecast, by End user
- 7.5.5.3. South Africa
- 7.5.5.3.1. Key market trends, growth factors and opportunities
- 7.5.5.3.2. Market size and forecast, by Product
- 7.5.5.3.3. Market size and forecast, by Type
- 7.5.5.3.4. Market size and forecast, by End user
- 7.5.5.4. Rest of LAMEA
- 7.5.5.4.1. Key market trends, growth factors and opportunities
- 7.5.5.4.2. Market size and forecast, by Product
- 7.5.5.4.3. Market size and forecast, by Type
- 7.5.5.4.4. Market size and forecast, by End user
- CHAPTER 8: COMPETITIVE LANDSCAPE
- 8.1. Introduction
- 8.2. Top winning strategies
- 8.3. Product Mapping of Top 10 Player
- 8.4. Competitive Dashboard
- 8.5. Competitive Heatmap
- 8.6. Top player positioning, 2022
- CHAPTER 9: COMPANY PROFILES
- 9.1. ConvaTec Group plc
- 9.1.1. Company overview
- 9.1.2. Key Executives
- 9.1.3. Company snapshot
- 9.1.4. Operating business segments
- 9.1.5. Product portfolio
- 9.1.6. Business performance
- 9.1.7. Key strategic moves and developments
- 9.2. 3M Company
- 9.2.1. Company overview
- 9.2.2. Key Executives
- 9.2.3. Company snapshot
- 9.2.4. Operating business segments
- 9.2.5. Product portfolio
- 9.2.6. Business performance
- 9.3. Cardinal Health Inc.
- 9.3.1. Company overview
- 9.3.2. Key Executives
- 9.3.3. Company snapshot
- 9.3.4. Operating business segments
- 9.3.5. Product portfolio
- 9.3.6. Business performance
- 9.3.7. Key strategic moves and developments
- 9.4. ORGANOGENESIS HOLDINGS INC.
- 9.4.1. Company overview
- 9.4.2. Key Executives
- 9.4.3. Company snapshot
- 9.4.4. Operating business segments
- 9.4.5. Product portfolio
- 9.4.6. Business performance
- 9.4.7. Key strategic moves and developments
- 9.5. Smith and Nephew plc.
- 9.5.1. Company overview
- 9.5.2. Key Executives
- 9.5.3. Company snapshot
- 9.5.4. Operating business segments
- 9.5.5. Product portfolio
- 9.5.6. Business performance
- 9.5.7. Key strategic moves and developments
- 9.6. B. Braun SE
- 9.6.1. Company overview
- 9.6.2. Key Executives
- 9.6.3. Company snapshot
- 9.6.4. Operating business segments
- 9.6.5. Product portfolio
- 9.6.6. Business performance
- 9.7. Coloplast
- 9.7.1. Company overview
- 9.7.2. Key Executives
- 9.7.3. Company snapshot
- 9.7.4. Operating business segments
- 9.7.5. Product portfolio
- 9.7.6. Business performance
- 9.8. Integra LifeSciences Holdings Corporation
- 9.8.1. Company overview
- 9.8.2. Key Executives
- 9.8.3. Company snapshot
- 9.8.4. Operating business segments
- 9.8.5. Product portfolio
- 9.8.6. Business performance
- 9.9. Molnlycke Health Care AB
- 9.9.1. Company overview
- 9.9.2. Key Executives
- 9.9.3. Company snapshot
- 9.9.4. Operating business segments
- 9.9.5. Product portfolio
- 9.9.6. Business performance
- 9.10. Essity Aktiebolag AB
- 9.10.1. Company overview
- 9.10.2. Key Executives
- 9.10.3. Company snapshot
- 9.10.4. Operating business segments
- 9.10.5. Product portfolio
- 9.10.6. Business performance
- 9.10.7. Key strategic moves and developments
- LIST OF TABLES
- TABLE 01. GLOBAL DIABETIC FOOT ULCER TREATMENT MARKET, BY PRODUCT, 2022-2032 ($MILLION)
- TABLE 02. DIABETIC FOOT ULCER TREATMENT MARKET FOR WOUND CARE DRESSINGS, BY REGION, 2022-2032 ($MILLION)
- TABLE 03. DIABETIC FOOT ULCER TREATMENT MARKET FOR WOUND CARE DEVICES, BY REGION, 2022-2032 ($MILLION)
- TABLE 04. GLOBAL WOUND CARE DEVICES DIABETIC FOOT ULCER TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 05. DIABETIC FOOT ULCER TREATMENT MARKET FOR BIOLOGICS, BY REGION, 2022-2032 ($MILLION)
- TABLE 06. DIABETIC FOOT ULCER TREATMENT MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
- TABLE 07. GLOBAL DIABETIC FOOT ULCER TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 08. DIABETIC FOOT ULCER TREATMENT MARKET FOR NEUROPATHIC ULCERS, BY REGION, 2022-2032 ($MILLION)
- TABLE 09. DIABETIC FOOT ULCER TREATMENT MARKET FOR ISCHEMIC ULCERS, BY REGION, 2022-2032 ($MILLION)
- TABLE 10. DIABETIC FOOT ULCER TREATMENT MARKET FOR NEUROISCHEMIC ULCERS, BY REGION, 2022-2032 ($MILLION)
- TABLE 11. GLOBAL DIABETIC FOOT ULCER TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 12. DIABETIC FOOT ULCER TREATMENT MARKET FOR HOSPITALS, BY REGION, 2022-2032 ($MILLION)
- TABLE 13. DIABETIC FOOT ULCER TREATMENT MARKET FOR HOMECARE SETTINGS, BY REGION, 2022-2032 ($MILLION)
- TABLE 14. DIABETIC FOOT ULCER TREATMENT MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
- TABLE 15. DIABETIC FOOT ULCER TREATMENT MARKET, BY REGION, 2022-2032 ($MILLION)
- TABLE 16. NORTH AMERICA DIABETIC FOOT ULCER TREATMENT MARKET, BY PRODUCT, 2022-2032 ($MILLION)
- TABLE 17. NORTH AMERICA DIABETIC FOOT ULCER TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 18. NORTH AMERICA DIABETIC FOOT ULCER TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 19. NORTH AMERICA DIABETIC FOOT ULCER TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
- TABLE 20. U.S. DIABETIC FOOT ULCER TREATMENT MARKET, BY PRODUCT, 2022-2032 ($MILLION)
- TABLE 21. U.S. DIABETIC FOOT ULCER TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 22. U.S. DIABETIC FOOT ULCER TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 23. CANADA DIABETIC FOOT ULCER TREATMENT MARKET, BY PRODUCT, 2022-2032 ($MILLION)
- TABLE 24. CANADA DIABETIC FOOT ULCER TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 25. CANADA DIABETIC FOOT ULCER TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 26. MEXICO DIABETIC FOOT ULCER TREATMENT MARKET, BY PRODUCT, 2022-2032 ($MILLION)
- TABLE 27. MEXICO DIABETIC FOOT ULCER TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 28. MEXICO DIABETIC FOOT ULCER TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 29. EUROPE DIABETIC FOOT ULCER TREATMENT MARKET, BY PRODUCT, 2022-2032 ($MILLION)
- TABLE 30. EUROPE DIABETIC FOOT ULCER TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 31. EUROPE DIABETIC FOOT ULCER TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 32. EUROPE DIABETIC FOOT ULCER TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
- TABLE 33. GERMANY DIABETIC FOOT ULCER TREATMENT MARKET, BY PRODUCT, 2022-2032 ($MILLION)
- TABLE 34. GERMANY DIABETIC FOOT ULCER TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 35. GERMANY DIABETIC FOOT ULCER TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 36. FRANCE DIABETIC FOOT ULCER TREATMENT MARKET, BY PRODUCT, 2022-2032 ($MILLION)
- TABLE 37. FRANCE DIABETIC FOOT ULCER TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 38. FRANCE DIABETIC FOOT ULCER TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 39. UK DIABETIC FOOT ULCER TREATMENT MARKET, BY PRODUCT, 2022-2032 ($MILLION)
- TABLE 40. UK DIABETIC FOOT ULCER TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 41. UK DIABETIC FOOT ULCER TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 42. ITALY DIABETIC FOOT ULCER TREATMENT MARKET, BY PRODUCT, 2022-2032 ($MILLION)
- TABLE 43. ITALY DIABETIC FOOT ULCER TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 44. ITALY DIABETIC FOOT ULCER TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 45. SPAIN DIABETIC FOOT ULCER TREATMENT MARKET, BY PRODUCT, 2022-2032 ($MILLION)
- TABLE 46. SPAIN DIABETIC FOOT ULCER TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 47. SPAIN DIABETIC FOOT ULCER TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 48. REST OF EUROPE DIABETIC FOOT ULCER TREATMENT MARKET, BY PRODUCT, 2022-2032 ($MILLION)
- TABLE 49. REST OF EUROPE DIABETIC FOOT ULCER TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 50. REST OF EUROPE DIABETIC FOOT ULCER TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 51. ASIA-PACIFIC DIABETIC FOOT ULCER TREATMENT MARKET, BY PRODUCT, 2022-2032 ($MILLION)
- TABLE 52. ASIA-PACIFIC DIABETIC FOOT ULCER TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 53. ASIA-PACIFIC DIABETIC FOOT ULCER TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 54. ASIA-PACIFIC DIABETIC FOOT ULCER TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
- TABLE 55. JAPAN DIABETIC FOOT ULCER TREATMENT MARKET, BY PRODUCT, 2022-2032 ($MILLION)
- TABLE 56. JAPAN DIABETIC FOOT ULCER TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 57. JAPAN DIABETIC FOOT ULCER TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 58. CHINA DIABETIC FOOT ULCER TREATMENT MARKET, BY PRODUCT, 2022-2032 ($MILLION)
- TABLE 59. CHINA DIABETIC FOOT ULCER TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 60. CHINA DIABETIC FOOT ULCER TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 61. INDIA DIABETIC FOOT ULCER TREATMENT MARKET, BY PRODUCT, 2022-2032 ($MILLION)
- TABLE 62. INDIA DIABETIC FOOT ULCER TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 63. INDIA DIABETIC FOOT ULCER TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 64. AUSTRALIA DIABETIC FOOT ULCER TREATMENT MARKET, BY PRODUCT, 2022-2032 ($MILLION)
- TABLE 65. AUSTRALIA DIABETIC FOOT ULCER TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 66. AUSTRALIA DIABETIC FOOT ULCER TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 67. SOUTH KOREA DIABETIC FOOT ULCER TREATMENT MARKET, BY PRODUCT, 2022-2032 ($MILLION)
- TABLE 68. SOUTH KOREA DIABETIC FOOT ULCER TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 69. SOUTH KOREA DIABETIC FOOT ULCER TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 70. REST OF ASIA-PACIFIC DIABETIC FOOT ULCER TREATMENT MARKET, BY PRODUCT, 2022-2032 ($MILLION)
- TABLE 71. REST OF ASIA-PACIFIC DIABETIC FOOT ULCER TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 72. REST OF ASIA-PACIFIC DIABETIC FOOT ULCER TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 73. LAMEA DIABETIC FOOT ULCER TREATMENT MARKET, BY PRODUCT, 2022-2032 ($MILLION)
- TABLE 74. LAMEA DIABETIC FOOT ULCER TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 75. LAMEA DIABETIC FOOT ULCER TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 76. LAMEA DIABETIC FOOT ULCER TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
- TABLE 77. BRAZIL DIABETIC FOOT ULCER TREATMENT MARKET, BY PRODUCT, 2022-2032 ($MILLION)
- TABLE 78. BRAZIL DIABETIC FOOT ULCER TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 79. BRAZIL DIABETIC FOOT ULCER TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 80. SAUDI ARABIA DIABETIC FOOT ULCER TREATMENT MARKET, BY PRODUCT, 2022-2032 ($MILLION)
- TABLE 81. SAUDI ARABIA DIABETIC FOOT ULCER TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 82. SAUDI ARABIA DIABETIC FOOT ULCER TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 83. SOUTH AFRICA DIABETIC FOOT ULCER TREATMENT MARKET, BY PRODUCT, 2022-2032 ($MILLION)
- TABLE 84. SOUTH AFRICA DIABETIC FOOT ULCER TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 85. SOUTH AFRICA DIABETIC FOOT ULCER TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 86. REST OF LAMEA DIABETIC FOOT ULCER TREATMENT MARKET, BY PRODUCT, 2022-2032 ($MILLION)
- TABLE 87. REST OF LAMEA DIABETIC FOOT ULCER TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 88. REST OF LAMEA DIABETIC FOOT ULCER TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 89. CONVATEC GROUP PLC: KEY EXECUTIVES
- TABLE 90. CONVATEC GROUP PLC: COMPANY SNAPSHOT
- TABLE 91. CONVATEC GROUP PLC: PRODUCT SEGMENTS
- TABLE 92. CONVATEC GROUP PLC: PRODUCT PORTFOLIO
- TABLE 93. CONVATEC GROUP PLC: KEY STRATERGIES
- TABLE 94. 3M COMPANY: KEY EXECUTIVES
- TABLE 95. 3M COMPANY: COMPANY SNAPSHOT
- TABLE 96. 3M COMPANY: PRODUCT SEGMENTS
- TABLE 97. 3M COMPANY: PRODUCT PORTFOLIO
- TABLE 98. CARDINAL HEALTH INC.: KEY EXECUTIVES
- TABLE 99. CARDINAL HEALTH INC.: COMPANY SNAPSHOT
- TABLE 100. CARDINAL HEALTH INC.: PRODUCT SEGMENTS
- TABLE 101. CARDINAL HEALTH INC.: PRODUCT PORTFOLIO
- TABLE 102. CARDINAL HEALTH INC.: KEY STRATERGIES
- TABLE 103. ORGANOGENESIS HOLDINGS INC.: KEY EXECUTIVES
- TABLE 104. ORGANOGENESIS HOLDINGS INC.: COMPANY SNAPSHOT
- TABLE 105. ORGANOGENESIS HOLDINGS INC.: PRODUCT SEGMENTS
- TABLE 106. ORGANOGENESIS HOLDINGS INC.: PRODUCT PORTFOLIO
- TABLE 107. ORGANOGENESIS HOLDINGS INC.: KEY STRATERGIES
- TABLE 108. SMITH AND NEPHEW PLC.: KEY EXECUTIVES
- TABLE 109. SMITH AND NEPHEW PLC.: COMPANY SNAPSHOT
- TABLE 110. SMITH AND NEPHEW PLC.: PRODUCT SEGMENTS
- TABLE 111. SMITH AND NEPHEW PLC.: PRODUCT PORTFOLIO
- TABLE 112. SMITH AND NEPHEW PLC.: KEY STRATERGIES
- TABLE 113. B. BRAUN SE: KEY EXECUTIVES
- TABLE 114. B. BRAUN SE: COMPANY SNAPSHOT
- TABLE 115. B. BRAUN SE: PRODUCT SEGMENTS
- TABLE 116. B. BRAUN SE: PRODUCT PORTFOLIO
- TABLE 117. COLOPLAST: KEY EXECUTIVES
- TABLE 118. COLOPLAST: COMPANY SNAPSHOT
- TABLE 119. COLOPLAST: PRODUCT SEGMENTS
- TABLE 120. COLOPLAST: PRODUCT PORTFOLIO
- TABLE 121. INTEGRA LIFESCIENCES HOLDINGS CORPORATION: KEY EXECUTIVES
- TABLE 122. INTEGRA LIFESCIENCES HOLDINGS CORPORATION: COMPANY SNAPSHOT
- TABLE 123. INTEGRA LIFESCIENCES HOLDINGS CORPORATION: PRODUCT SEGMENTS
- TABLE 124. INTEGRA LIFESCIENCES HOLDINGS CORPORATION: PRODUCT PORTFOLIO
- TABLE 125. MOLNLYCKE HEALTH CARE AB: KEY EXECUTIVES
- TABLE 126. MOLNLYCKE HEALTH CARE AB: COMPANY SNAPSHOT
- TABLE 127. MOLNLYCKE HEALTH CARE AB: PRODUCT SEGMENTS
- TABLE 128. MOLNLYCKE HEALTH CARE AB: PRODUCT PORTFOLIO
- TABLE 129. ESSITY AKTIEBOLAG AB: KEY EXECUTIVES
- TABLE 130. ESSITY AKTIEBOLAG AB: COMPANY SNAPSHOT
- TABLE 131. ESSITY AKTIEBOLAG AB: PRODUCT SEGMENTS
- TABLE 132. ESSITY AKTIEBOLAG AB: PRODUCT PORTFOLIO
- TABLE 133. ESSITY AKTIEBOLAG AB: KEY STRATERGIES
- LIST OF FIGURES
- FIGURE 01. DIABETIC FOOT ULCER TREATMENT MARKET, 2022-2032
- FIGURE 02. SEGMENTATION OF DIABETIC FOOT ULCER TREATMENT MARKET, 2022-2032
- FIGURE 03. TOP INVESTMENT POCKETS IN DIABETIC FOOT ULCER TREATMENT MARKET (2023-2032)
- FIGURE 04. HIGH BARGAINING POWER OF SUPPLIERS
- FIGURE 05. MODERATE THREAT OF NEW ENTRANTS
- FIGURE 06. MODERATE THREAT OF SUBSTITUTES
- FIGURE 07. LOW INTENSITY OF RIVALRY
- FIGURE 08. HIGH BARGAINING POWER OF BUYERS
- FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALDIABETIC FOOT ULCER TREATMENT MARKET
- FIGURE 09. DIABETIC FOOT ULCER TREATMENT MARKET, BY PRODUCT, 2022(%)
- FIGURE 10. COMPARATIVE SHARE ANALYSIS OF DIABETIC FOOT ULCER TREATMENT MARKET FOR WOUND CARE DRESSINGS, BY COUNTRY 2022 AND 2032(%)
- FIGURE 11. COMPARATIVE SHARE ANALYSIS OF DIABETIC FOOT ULCER TREATMENT MARKET FOR WOUND CARE DEVICES, BY COUNTRY 2022 AND 2032(%)
- FIGURE 12. COMPARATIVE SHARE ANALYSIS OF DIABETIC FOOT ULCER TREATMENT MARKET FOR BIOLOGICS, BY COUNTRY 2022 AND 2032(%)
- FIGURE 13. COMPARATIVE SHARE ANALYSIS OF DIABETIC FOOT ULCER TREATMENT MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
- FIGURE 14. DIABETIC FOOT ULCER TREATMENT MARKET, BY TYPE, 2022(%)
- FIGURE 15. COMPARATIVE SHARE ANALYSIS OF DIABETIC FOOT ULCER TREATMENT MARKET FOR NEUROPATHIC ULCERS, BY COUNTRY 2022 AND 2032(%)
- FIGURE 16. COMPARATIVE SHARE ANALYSIS OF DIABETIC FOOT ULCER TREATMENT MARKET FOR ISCHEMIC ULCERS, BY COUNTRY 2022 AND 2032(%)
- FIGURE 17. COMPARATIVE SHARE ANALYSIS OF DIABETIC FOOT ULCER TREATMENT MARKET FOR NEUROISCHEMIC ULCERS, BY COUNTRY 2022 AND 2032(%)
- FIGURE 18. DIABETIC FOOT ULCER TREATMENT MARKET, BY END USER, 2022(%)
- FIGURE 19. COMPARATIVE SHARE ANALYSIS OF DIABETIC FOOT ULCER TREATMENT MARKET FOR HOSPITALS, BY COUNTRY 2022 AND 2032(%)
- FIGURE 20. COMPARATIVE SHARE ANALYSIS OF DIABETIC FOOT ULCER TREATMENT MARKET FOR HOMECARE SETTINGS, BY COUNTRY 2022 AND 2032(%)
- FIGURE 21. COMPARATIVE SHARE ANALYSIS OF DIABETIC FOOT ULCER TREATMENT MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
- FIGURE 22. DIABETIC FOOT ULCER TREATMENT MARKET BY REGION, 2022
- FIGURE 23. U.S. DIABETIC FOOT ULCER TREATMENT MARKET, 2022-2032 ($MILLION)
- FIGURE 24. CANADA DIABETIC FOOT ULCER TREATMENT MARKET, 2022-2032 ($MILLION)
- FIGURE 25. MEXICO DIABETIC FOOT ULCER TREATMENT MARKET, 2022-2032 ($MILLION)
- FIGURE 26. GERMANY DIABETIC FOOT ULCER TREATMENT MARKET, 2022-2032 ($MILLION)
- FIGURE 27. FRANCE DIABETIC FOOT ULCER TREATMENT MARKET, 2022-2032 ($MILLION)
- FIGURE 28. UK DIABETIC FOOT ULCER TREATMENT MARKET, 2022-2032 ($MILLION)
- FIGURE 29. ITALY DIABETIC FOOT ULCER TREATMENT MARKET, 2022-2032 ($MILLION)
- FIGURE 30. SPAIN DIABETIC FOOT ULCER TREATMENT MARKET, 2022-2032 ($MILLION)
- FIGURE 31. REST OF EUROPE DIABETIC FOOT ULCER TREATMENT MARKET, 2022-2032 ($MILLION)
- FIGURE 32. JAPAN DIABETIC FOOT ULCER TREATMENT MARKET, 2022-2032 ($MILLION)
- FIGURE 33. CHINA DIABETIC FOOT ULCER TREATMENT MARKET, 2022-2032 ($MILLION)
- FIGURE 34. INDIA DIABETIC FOOT ULCER TREATMENT MARKET, 2022-2032 ($MILLION)
- FIGURE 35. AUSTRALIA DIABETIC FOOT ULCER TREATMENT MARKET, 2022-2032 ($MILLION)
- FIGURE 36. SOUTH KOREA DIABETIC FOOT ULCER TREATMENT MARKET, 2022-2032 ($MILLION)
- FIGURE 37. REST OF ASIA-PACIFIC DIABETIC FOOT ULCER TREATMENT MARKET, 2022-2032 ($MILLION)
- FIGURE 38. BRAZIL DIABETIC FOOT ULCER TREATMENT MARKET, 2022-2032 ($MILLION)
- FIGURE 39. SAUDI ARABIA DIABETIC FOOT ULCER TREATMENT MARKET, 2022-2032 ($MILLION)
- FIGURE 40. SOUTH AFRICA DIABETIC FOOT ULCER TREATMENT MARKET, 2022-2032 ($MILLION)
- FIGURE 41. REST OF LAMEA DIABETIC FOOT ULCER TREATMENT MARKET, 2022-2032 ($MILLION)
- FIGURE 42. TOP WINNING STRATEGIES, BY YEAR
- FIGURE 43. TOP WINNING STRATEGIES, BY DEVELOPMENT
- FIGURE 44. TOP WINNING STRATEGIES, BY COMPANY
- FIGURE 45. PRODUCT MAPPING OF TOP 10 PLAYERS
- FIGURE 46. COMPETITIVE DASHBOARD
- FIGURE 47. COMPETITIVE HEATMAP: DIABETIC FOOT ULCER TREATMENT MARKET
- FIGURE 48. TOP PLAYER POSITIONING, 2022
- FIGURE 49. CONVATEC GROUP PLC: NET REVENUE, 2020-2022 ($MILLION)
- FIGURE 50. CONVATEC GROUP PLC: REVENUE SHARE BY SEGMENT, 2022 (%)
- FIGURE 51. CONVATEC GROUP PLC: REVENUE SHARE BY REGION, 2022 (%)
- FIGURE 52. 3M COMPANY: NET REVENUE, 2020-2022 ($MILLION)
- FIGURE 53. 3M COMPANY: RESEARCH & DEVELOPMENT EXPENDITURE, 2020-2022 ($MILLION)
- FIGURE 54. 3M COMPANY: REVENUE SHARE BY SEGMENT, 2022 (%)
- FIGURE 55. 3M COMPANY: REVENUE SHARE BY REGION, 2022 (%)
- FIGURE 56. CARDINAL HEALTH INC.: NET REVENUE, 2020-2022 ($MILLION)
- FIGURE 57. CARDINAL HEALTH INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
- FIGURE 58. CARDINAL HEALTH INC.: REVENUE SHARE BY REGION, 2022 (%)
- FIGURE 59. ORGANOGENESIS HOLDINGS INC.: NET REVENUE, 2020-2022 ($MILLION)
- FIGURE 60. SMITH AND NEPHEW PLC.: NET REVENUE, 2020-2022 ($MILLION)
- FIGURE 61. SMITH AND NEPHEW PLC.: REVENUE SHARE BY SEGMENT, 2022 (%)
- FIGURE 62. SMITH AND NEPHEW PLC.: REVENUE SHARE BY REGION, 2022 (%)
- FIGURE 63. B. BRAUN SE: NET SALES, 2020-2022 ($MILLION)
- FIGURE 64. B. BRAUN SE: REVENUE SHARE BY SEGMENT, 2022 (%)
- FIGURE 65. B. BRAUN SE: REVENUE SHARE BY REGION, 2022 (%)
- FIGURE 66. COLOPLAST: NET REVENUE, 2020-2022 ($MILLION)
- FIGURE 67. COLOPLAST: REVENUE SHARE BY SEGMENT, 2022 (%)
- FIGURE 68. COLOPLAST: REVENUE SHARE BY REGION, 2022 (%)
- FIGURE 69. INTEGRA LIFESCIENCES HOLDINGS CORPORATION: NET REVENUE, 2020-2022 ($MILLION)
- FIGURE 70. INTEGRA LIFESCIENCES HOLDINGS CORPORATION: REVENUE SHARE BY SEGMENT, 2022 (%)
- FIGURE 71. INTEGRA LIFESCIENCES HOLDINGS CORPORATION: REVENUE SHARE BY REGION, 2022 (%)
- FIGURE 72. MOLNLYCKE HEALTH CARE AB: NET REVENUE, 2020-2022 ($MILLION)
- FIGURE 73. MOLNLYCKE HEALTH CARE AB: REVENUE SHARE BY SEGMENT, 2022 (%)
- FIGURE 74. MOLNLYCKE HEALTH CARE AB: REVENUE SHARE BY REGION, 2022 (%)
- FIGURE 75. ESSITY AKTIEBOLAG AB: NET REVENUE, 2020-2022 ($MILLION)
- FIGURE 76. ESSITY AKTIEBOLAG AB: REVENUE SHARE BY SEGMENT, 2022 (%)
- FIGURE 77. ESSITY AKTIEBOLAG AB: REVENUE SHARE BY REGION, 2022 (%)
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook